^
    Back
    Association details:
    Biomarker:KIFC1 expression
    Cancer:Bladder Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Med
    Title:

    KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer

    Published date:
    10/21/2021
    Excerpt:
    This study aimed to analyze KIFC1 expression and examine KIFC1 involvement in cisplatin resistance in bladder cancer (BC)....Kaplan-Meier analysis indicated that prognosis was poor among KIFC1-positive BC patients treated with cisplatin-based chemotherapy.
    DOI:
    https://doi.org/10.3390/jcm10214837